B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases

Shiori Kondo, Tomoyuki Akashi, Hitoshi Katsuta, Ryuichi Iwakiri, Keizo Anzai, Seiho Nagafuchi, Yoshiyuki Niho, Mine Harada

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The levels and types of immune responses are determined dependent on the extent of pathogen invasion, reactions to antigens mediated by macrophage-dendritic cells, T cells and antibodies. Recently, accumulating evidence suggests that B cells also play an important role in the regulation of immune responses. Here we have made a review to present a role of B cells in determining the level of immune responses and discussed about the clinical significance of B cell-targeted therapy in patients with autoimmune diseases. Type 1 diabetes is a T cell-mediated autoimmune disease characterized by the destruction of insulin-producing pancreatic beta cells. We and other groups have elucidated that B cells play a critical role in the development of insulitis and diabetes, as B-cell-deficient NOD mice are protected from developing type 1 diabetes. B cells are essential for the T cell receptor clonotype spreading of islet-infiltrating T cells, indicating that B cells may play a role in determining the level of immune responses by antigen presentation to antigen specific T cells. There are now numerous case reports and small series of clinical trials regarding rituximab therapy in autoimmune diseases, such as refractory autoimmune hemolytic anemia, IgM antibody-associated polyneuropathy, systemic lupus erythematosus and rheumatoid arthritis. Rituximab is a genetically engineered chimeric anti-CD 20 monoclonal antibody that is approved for the treatment of lymphoma. CD20 is a B-cell surface antigen that is expressed only on pre- B and mature B cells. Thus, rituximab causes a selective transient depletion of the CD20+ B -cell subpopulation. Rationale and strategy for targeting B cells in the treatment of autoimmune diseases consist of the inhibition of antigen-presentation and co-stimulation that induces T cell expansion and activation. Further careful mechanistic studies are required to develop therapies in patients with autoimmune diseases.

Original languageEnglish
Pages (from-to)86-92
Number of pages7
JournalFukuoka igaku zasshi = Hukuoka acta medica
Volume96
Issue number4
Publication statusPublished - Jan 1 2005
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Autoimmune Diseases
B-Lymphocytes
T-Lymphocytes
Antigen Presentation
Type 1 Diabetes Mellitus
Antigens
Autoimmune Hemolytic Anemia
Inbred NOD Mouse
Polyneuropathies
Antibodies
Histocompatibility Antigens Class II
Insulin-Secreting Cells
Therapeutics
Surface Antigens
T-Cell Antigen Receptor
Systemic Lupus Erythematosus
Dendritic Cells
Immunoglobulin M
Lymphoma

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases. / Kondo, Shiori; Akashi, Tomoyuki; Katsuta, Hitoshi; Iwakiri, Ryuichi; Anzai, Keizo; Nagafuchi, Seiho; Niho, Yoshiyuki; Harada, Mine.

In: Fukuoka igaku zasshi = Hukuoka acta medica, Vol. 96, No. 4, 01.01.2005, p. 86-92.

Research output: Contribution to journalReview article

Kondo, Shiori ; Akashi, Tomoyuki ; Katsuta, Hitoshi ; Iwakiri, Ryuichi ; Anzai, Keizo ; Nagafuchi, Seiho ; Niho, Yoshiyuki ; Harada, Mine. / B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases. In: Fukuoka igaku zasshi = Hukuoka acta medica. 2005 ; Vol. 96, No. 4. pp. 86-92.
@article{52c529ddf24b408db2f45232da39a739,
title = "B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases",
abstract = "The levels and types of immune responses are determined dependent on the extent of pathogen invasion, reactions to antigens mediated by macrophage-dendritic cells, T cells and antibodies. Recently, accumulating evidence suggests that B cells also play an important role in the regulation of immune responses. Here we have made a review to present a role of B cells in determining the level of immune responses and discussed about the clinical significance of B cell-targeted therapy in patients with autoimmune diseases. Type 1 diabetes is a T cell-mediated autoimmune disease characterized by the destruction of insulin-producing pancreatic beta cells. We and other groups have elucidated that B cells play a critical role in the development of insulitis and diabetes, as B-cell-deficient NOD mice are protected from developing type 1 diabetes. B cells are essential for the T cell receptor clonotype spreading of islet-infiltrating T cells, indicating that B cells may play a role in determining the level of immune responses by antigen presentation to antigen specific T cells. There are now numerous case reports and small series of clinical trials regarding rituximab therapy in autoimmune diseases, such as refractory autoimmune hemolytic anemia, IgM antibody-associated polyneuropathy, systemic lupus erythematosus and rheumatoid arthritis. Rituximab is a genetically engineered chimeric anti-CD 20 monoclonal antibody that is approved for the treatment of lymphoma. CD20 is a B-cell surface antigen that is expressed only on pre- B and mature B cells. Thus, rituximab causes a selective transient depletion of the CD20+ B -cell subpopulation. Rationale and strategy for targeting B cells in the treatment of autoimmune diseases consist of the inhibition of antigen-presentation and co-stimulation that induces T cell expansion and activation. Further careful mechanistic studies are required to develop therapies in patients with autoimmune diseases.",
author = "Shiori Kondo and Tomoyuki Akashi and Hitoshi Katsuta and Ryuichi Iwakiri and Keizo Anzai and Seiho Nagafuchi and Yoshiyuki Niho and Mine Harada",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "96",
pages = "86--92",
journal = "Fukuoka Acta Medica",
issn = "0016-254X",
publisher = "福岡医学会",
number = "4",

}

TY - JOUR

T1 - B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases

AU - Kondo, Shiori

AU - Akashi, Tomoyuki

AU - Katsuta, Hitoshi

AU - Iwakiri, Ryuichi

AU - Anzai, Keizo

AU - Nagafuchi, Seiho

AU - Niho, Yoshiyuki

AU - Harada, Mine

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The levels and types of immune responses are determined dependent on the extent of pathogen invasion, reactions to antigens mediated by macrophage-dendritic cells, T cells and antibodies. Recently, accumulating evidence suggests that B cells also play an important role in the regulation of immune responses. Here we have made a review to present a role of B cells in determining the level of immune responses and discussed about the clinical significance of B cell-targeted therapy in patients with autoimmune diseases. Type 1 diabetes is a T cell-mediated autoimmune disease characterized by the destruction of insulin-producing pancreatic beta cells. We and other groups have elucidated that B cells play a critical role in the development of insulitis and diabetes, as B-cell-deficient NOD mice are protected from developing type 1 diabetes. B cells are essential for the T cell receptor clonotype spreading of islet-infiltrating T cells, indicating that B cells may play a role in determining the level of immune responses by antigen presentation to antigen specific T cells. There are now numerous case reports and small series of clinical trials regarding rituximab therapy in autoimmune diseases, such as refractory autoimmune hemolytic anemia, IgM antibody-associated polyneuropathy, systemic lupus erythematosus and rheumatoid arthritis. Rituximab is a genetically engineered chimeric anti-CD 20 monoclonal antibody that is approved for the treatment of lymphoma. CD20 is a B-cell surface antigen that is expressed only on pre- B and mature B cells. Thus, rituximab causes a selective transient depletion of the CD20+ B -cell subpopulation. Rationale and strategy for targeting B cells in the treatment of autoimmune diseases consist of the inhibition of antigen-presentation and co-stimulation that induces T cell expansion and activation. Further careful mechanistic studies are required to develop therapies in patients with autoimmune diseases.

AB - The levels and types of immune responses are determined dependent on the extent of pathogen invasion, reactions to antigens mediated by macrophage-dendritic cells, T cells and antibodies. Recently, accumulating evidence suggests that B cells also play an important role in the regulation of immune responses. Here we have made a review to present a role of B cells in determining the level of immune responses and discussed about the clinical significance of B cell-targeted therapy in patients with autoimmune diseases. Type 1 diabetes is a T cell-mediated autoimmune disease characterized by the destruction of insulin-producing pancreatic beta cells. We and other groups have elucidated that B cells play a critical role in the development of insulitis and diabetes, as B-cell-deficient NOD mice are protected from developing type 1 diabetes. B cells are essential for the T cell receptor clonotype spreading of islet-infiltrating T cells, indicating that B cells may play a role in determining the level of immune responses by antigen presentation to antigen specific T cells. There are now numerous case reports and small series of clinical trials regarding rituximab therapy in autoimmune diseases, such as refractory autoimmune hemolytic anemia, IgM antibody-associated polyneuropathy, systemic lupus erythematosus and rheumatoid arthritis. Rituximab is a genetically engineered chimeric anti-CD 20 monoclonal antibody that is approved for the treatment of lymphoma. CD20 is a B-cell surface antigen that is expressed only on pre- B and mature B cells. Thus, rituximab causes a selective transient depletion of the CD20+ B -cell subpopulation. Rationale and strategy for targeting B cells in the treatment of autoimmune diseases consist of the inhibition of antigen-presentation and co-stimulation that induces T cell expansion and activation. Further careful mechanistic studies are required to develop therapies in patients with autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=23844517518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844517518&partnerID=8YFLogxK

M3 - Review article

C2 - 15991605

AN - SCOPUS:23844517518

VL - 96

SP - 86

EP - 92

JO - Fukuoka Acta Medica

JF - Fukuoka Acta Medica

SN - 0016-254X

IS - 4

ER -